Singapore, July 9 -- The Health Sciences Authority received information related to the study titled 'Phase Ib/II Study of Tislelizumab in Combination with Bevacizumab and Capecitabine in Advanced Solid Tumors with Evaluation in Immunotherapy-Resistant and Central Nervous System Disease (TIBEC)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Lee Soo Chin
Published by HT Digital Content Services with permission from Health Daily Digest....